timing of immunotherapy discontinuation remains challenging in melanoma
Published 4 years ago • 684 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:25
dr. weber on discontinuing immunotherapy in melanoma
-
1:28
immunotherapy versus targeted therapy for advanced melanoma
-
5:30
sequencing and timing: unanswered questions in melanoma
-
1:36
dr. daud on the challenges of treating metastatic melanoma with braf inhibitor monotherapy
-
1:18
dr. lewis on sequencing immunotherapy and targeted therapy in melanoma
-
4:52
treatment of metastatic melanoma beyond progression
-
2:05
dr. luke on challenges with immunotherapy in melanoma
-
1:30
treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
-
7:03
patient selection in melanoma: immunotherapy vs targeted therapy
-
5:52
unresectable melanoma—targeted or immunotherapy?
-
3:09
challenges facing the field of melanoma
-
25:50
melanoma | 2022 oneoncology conference
-
23:58
personalizing melanoma treatment for stage iii and stage iv patients
-
2:43
clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy
-
8:35
long-term results for immunotherapy in melanoma
-
0:51
expert cautions on use of antibiotics with immunotherapy in melanoma
-
2:19
immunotherapy and advances in melanoma | upmc video rounds
-
34:47
immuno-oncology, immune therapy, pd-1 in melanoma - omid hamid md
-
2:29
braf mutated melanoma: targeted or immunotherapy?